KPTIKaryopharm Therapeutics Inc
$8.72
$0.07
(0.78%)
Closed $9.07
$0.35
(3.86%)
After Hours
Reported EarningsMay 14
Mkt Cap$203.97M
Vol219,177.00
Fundamentals
Mkt Cap
$203.97M
Volume
-
52W High
$10.99
52W Low
$3.65
PE Ratio
-0.60
Avg. Volume
461,234.13
EPS (Annual)
-$17.93
Rev/Employee
$640,644.74
Earnings
May 14
62
Bullish Sentiment
How do you feel about KPTI?
Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026
Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026 Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026 PR Newswire NEWTON, Mass., June 3, 2026 NEWTON, Mass., June 3, 2026 /PRNewswire/ -- Karyopharm...
PR Newswire
Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026 Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026 PR Newswire NEWTON...
PR Newswire
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PR Newswire NEWTON, Mass., June 1, 2026 NEWTON, Mass., June 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq...
PR Newswire
Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation
Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO...
PR Newswire
Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference
Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference PR Newswire NEWTON, Mass., May 28, 2026 NEWTON, Mass., May 28, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a...
PR Newswire
Wall Street Analysts Think Karyopharm Therapeutics (KPTI) Could Surge 70.46%: Read This Before Placing a Bet
The consensus price target hints at a 70.5% upside potential for Karyopharm Therapeutics (KPTI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks
Karyopharm Therapeutics Q1 Earnings Call Highlights
Karyopharm Therapeutics Q1 Earnings Call Highlights...
Yahoo! Finance: News
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Beats Revenue Estimates
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of +14.48% and +3.34%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment
Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3...
PR Newswire
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
Verrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of +30.51% and +6.87%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
<
1
2
...
>
Advertisement|Remove ads.
Latest KPTI News
ViewKaryopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026
PR Newswire
Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
PR Newswire
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
Advertisement|Remove ads.